Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
The BRIGHT-4 trial demonstrates that bivalirudin with prolonged infusion reduces 30-day mortality and major bleeding compared to heparin in STEMI patients undergoing radial primary PCI, benefiting both low and higher bleeding risk groups.
This study reveals distinct thromboembolic, bleeding, and mortality risks based on antiseizure medication selection in epilepsy patients receiving direct oral anticoagulants, highlighting the critical role of ASM choice on patient safety an
The AZALEA-TIMI 71 study demonstrates that factor XI inhibition with abelacimab reduces bleeding risk in atrial fibrillation patients regardless of prior oral anticoagulation experience, with a potentially greater absolute benefit in antico
A multicomponent stewardship intervention significantly reduced inappropriate antiplatelet prescription among patients on DOACs, decreasing bleeding risk, particularly in stable coronary artery disease.
Shorter pre-treatment fibrin clot lysis time independently predicts higher bleeding risk in AF patients on oral anticoagulation, as evidenced by the ARISTOTLE trial.
A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populat
A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer al
A nationwide cohort study demonstrates that NSAID use in patients with atrial fibrillation on oral anticoagulants nearly doubles the risk of hospital-diagnosed bleeding, with significant risks observed across all anticoagulant types and mul
In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding
ASPREE randomized ~19,000 older adults to low‑dose aspirin or placebo. Over ~4.7 years, aspirin did not improve disability‑free survival or reduce cardiovascular events, increased major bleeding, and showed a surprising rise in cancer‑relat
This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for thos
The STOPDAPT-3 randomized trial compared aspirin-free low-dose prasugrel monotherapy with standard dual antiplatelet therapy, revealing noninferior cardiovascular outcomes but no reduction in major bleeding after PCI, with signals of increa
Low-dose aspirin added to anticoagulation for cancer-associated VTE reduces recurrence and PE-related mortality but increases bleeding risk, without improving overall survival or net clinical benefit over 6 months.
The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.
Posthoc analysis of TWILIGHT shows that ischemic risk rises with the number of high‑risk features, bleeding does not, and ticagrelor monotherapy after 3 months reduces bleeding versus ticagrelor plus aspirin without increasing ischemic even